Last close As at 12/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: TMT
EMIS reported FY22 results that were in line with management expectations. Revenue increased 4% y-o-y, adjusted operating profit increased 10% and adjusted EPS grew 10%. The company closed the year with net cash of £45.9m, reduced from the prior year due to several bolt-on acquisitions in the year. A final dividend of 21.1p was declared for a full year dividend of 38.7p.
EMIS Group |
FY22 results in line |
FY22 results |
Software and comp services |
30 May 2023 |
Share price performance
Business description
Next events
Analyst
For the purposes of the Takeover Code, Edison Investment Research is deemed to be connected with EMIS Group. EMIS Group is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||
EMIS reported FY22 results that were in line with management expectations. Revenue increased 4% y-o-y, adjusted operating profit increased 10% and adjusted EPS grew 10%. The company closed the year with net cash of £45.9m, reduced from the prior year due to several bolt-on acquisitions in the year. A final dividend of 21.1p was declared for a full year dividend of 38.7p.
Year end |
Revenue (£m) |
PBT* |
Diluted EPS* (p) |
EMIS adjusted diluted EPS** (p) |
DPS |
P/E |
12/19 |
159.5 |
41.0 |
53.5 |
51.1 |
31.2 |
25.2 |
12/20 |
159.5 |
43.4 |
56.4 |
50.4 |
32.0 |
23.9 |
12/21 |
168.2 |
43.5 |
55.0 |
55.5 |
35.2 |
24.5 |
12/22 |
175.4 |
48.1 |
60.9 |
61.2 |
38.7 |
22.1 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. **EMIS adjusted EPS – cash accounts for development costs and excludes exceptional items and amortisation of acquired intangibles.
EPS and dividend growth of 10% for FY22
EMIS reported revenue of £175.4m for FY22, up 4.2% y-o-y (+1.6% organic) and adjusted operating profit of £47.7m (+9.5% y-o-y, 27.2% margin). EMIS Health's planned reduction of its lower-margin partner resale business acted as a drag on revenues but improved profitability. EMIS Enterprise saw strong revenue growth and margin expansion. The technology transformation programme incurred exceptional costs of £8.2m with the ongoing bid for EMIS generating exceptional costs of £4.6m. A 10% increase in adjusted diluted EPS supports a 10% increase in the full year dividend.
Several bolt-on deals reduced cash
In FY22, EMIS acquired Edenbridge for up to £10m (£5.5m paid to date) and FourteenFish for £14.7m (net of cash acquired). The company also bought out the remaining 50% stake in the Healthcare Gateway for £14m in cash (£12.6m net of cash acquired). Combined, these deals contributed £4.4m to revenue and £1.7m to adjusted operating profit in FY22. Total acquisition-related payments of £35m resulted in net cash declining by 28% to £45.9m.
Takeover progress: Targeting completion by Q124
On 17 June 2022, the boards of Bordeaux (Bidco) and EMIS announced that they had reached agreement on the terms of a recommended all-cash offer pursuant to which Bordeaux, an affiliate of Optum UK and a wholly owned subsidiary of UnitedHealth Group, will acquire the entire issued and to be issued ordinary share capital of EMIS for a price of 1,925p per share. The Competition and Markets Authority (CMA) recently completed its Phase 1 investigation in which it identified concerns that the deal could affect competition. It rejected the remedies proposed by Bidco to remedy these and has now opened a Phase 2 investigation. Bidco and EMIS intend to proceed with the investigation and EMIS anticipates the deal closing in Q423 or Q124. The court has approved the extension of the long-stop date from 30 June 2023 to 30 June 2024.
Review of FY22 results
EMIS reported revenue growth of 4.2% for FY22 (1.6% organic). Recurring revenue (82% of total revenue) increased 6.3% y-o-y. Adjusted operating profit increased 9.5% over the same period (5.7% organic) resulting in operating margin expansion of 1.3pp to 27.2%. Reported operating profit includes exceptional costs of £12.8m (see below for detail) and profit before tax includes a gain on revaluation of a previously held interest in a joint venture of £10.7m (more detail below). Adjusted diluted EPS increased 10.3% y-o-y. The company announced a final dividend of 21.1p, which combined with the interim dividend of 17.6p results in a full year dividend of 38.7p, up 9.9% y-o-y.
Exhibit 1: FY22 results highlights
£'000s |
FY21 |
FY22 |
y-o-y |
Revenues |
168,226 |
175,373 |
4.2% |
Normalised operating profit |
43,246 |
47,631 |
10.1% |
Normalised operating margin |
25.7% |
27.2% |
1.5% |
Reported operating profit |
35,785 |
27,746 |
(22.5%) |
EMIS adjusted operating profit |
43,533 |
47,686 |
9.5% |
Adjusted operating margin |
25.9% |
27.2% |
1.3% |
Normalised diluted EPS – p |
55.0 |
60.9 |
10.7% |
Reported basic EPS – p |
46.2 |
52.5 |
13.8% |
EMIS adjusted diluted EPS – p |
55.5 |
61.2 |
10.3% |
Dividend per share – p |
35.2 |
38.7 |
9.9% |
Net cash/(debt) |
64,042 |
45,918 |
(28.3%) |
Source: EMIS
Net cash declined 28% y-o-y, mainly due to acquisition-related payments. Net cash from operating activities totalled £46.2m (FY22: £42.5m) and was after £10.2m in cash costs for exceptional items. Capex totalled £7.1m (FY22: £6.4m), payments relating to acquisitions totalled £34.6m and dividend payments totalled £22.2m.
High level of exceptional costs
The company charged a total of £12.8m in exceptional costs in FY22. Costs relating to the planned takeover by UnitedHealth made up £4.6m of this. The remaining £8.2m related to the technology transformation programme that is designed to update EMIS Web. The EMIS Web modernisation programme is focused on improving the user experience and customer retention.
Acquisition-related activity in FY22
The impact of acquisitions on FY22 results came from four deals:
■
Edenbridge Healthcare: acquired for £4m in cash on 14 January 2022. Paid out £1.5m in contingent consideration with a further £4.5m on the balance sheet at year-end (£1.5m short-term, £3.0m long-term).
■
FourteenFish: acquired on 1 March 2022 for £15.6m in cash or £14.4m net of acquired cash. Paid out contingent consideration of £0.3m in the year.
■
Healthcare Gateway: EMIS set up a 50/50 joint venture with INPS (number three GP software supplier in the UK, owned by Cegedim) back in 2010. The JV’s technology is known as the medical interoperability gateway (MIG) and is designed to help connect real-time patient data between different healthcare settings. In October 2022, EMIS acquired INPS’s 50% stake for £14m (or £12.4m net of cash acquired) and reported a gain on revaluation of its JV stake of £10.7m (treated as an exceptional item within PBT but not included in operating profit).
■
Pinnacle: acquired in 2020. Made the final contingent consideration payment of £2m.
Divisional performance
Exhibit 2: Divisional revenue and operating profit
£m |
FY21 |
FY22 |
y-o-y |
Revenues |
|||
EMIS Health |
108.0 |
103.9 |
(3.7%) |
EMIS Enterprise |
60.3 |
71.5 |
18.6% |
Total |
168.2 |
175.4 |
4.2% |
Adjusted operating profit |
|||
EMIS Health |
26.3 |
26.4 |
0.2% |
EMIS Enterprise |
18.9 |
22.9 |
20.8% |
Central costs |
(1.7) |
(1.6) |
(9.6%) |
Total adjusted operating profit |
43.5 |
47.7 |
9.5% |
Reported operating profit |
|||
EMIS Health |
22.1 |
23.9 |
8.5% |
EMIS Enterprise |
15.4 |
18.1 |
17.4% |
Central costs |
(1.7) |
(1.6) |
(9.6%) |
Total reported operating profit |
35.8 |
40.5 |
13.2% |
Adjusted operating margin |
|||
EMIS Health |
24.4% |
25.4% |
1.0% |
EMIS Enterprise |
31.4% |
32.0% |
0.6% |
Total adjusted operating margin |
25.9% |
27.2% |
1.3% |
Reported operating margin |
|||
EMIS Health |
20.4% |
23.0% |
2.6% |
EMIS Enterprise |
25.6% |
25.4% |
(0.3%) |
Total reported operating margin |
21.3% |
23.1% |
1.8% |
Source: EMIS
EMIS Health
Revenue from EMIS Health declined 3.7% y-o-y, mainly due to the company phasing out lower-margin resale partner business. Adjusted operating profit was essentially flat over the year with the adjusted operating margin increasing by 1pp to 25.4%.
EMIS maintained its GP market share of 58% in the UK. In acute A&E software and community, it maintained its number two positions, with market share of 19% (FY21: 21%) and 19% (FY21: 20%) respectively.
In Wales and Northern Ireland, EMIS is working with the relevant national healthcare organisations to align its software development plans with their requirements. The business withdrew from the Scottish GP IT Re-provisioning Framework during FY22, deciding to prioritise the EMIS Web modernisation programme over bespoke development for the framework. It will continue to support customers in Scotland.
The business was appointed to the NHS Digital Tech Innovation Framework (TIF) and its technology roadmap remains aligned with NHS England strategy. NHS England is currently forming plans for the Digital Primary Care Framework (DPCF), which will be the successor to the GP IT Futures framework in England.
EMIS Enterprise
Revenue from EMIS Enterprise increased 18.6% y-o-y, partly due to contributions from the Edenbridge and FourteenFish acquisitions as well as from strong growth in analytics and the Pinnacle business. Adjusted operating profit increased 20.8% with the adjusted operating margin increasing by 0.6pp to 32.0%.
■
The business maintained its lead in the community pharmacy market with 39% market share and its number two position in hospital pharmacy with a 33% share (FY21: 36%).
■
Registered users of Patient Access increased to 16.1m from 14.0m last year. Users booked 1.3m GP appointments (FY21: 1.5m) and ordered 19m prescriptions (FY21: 22m). Patient.info reported 67m unique users viewing 135m pages in FY22 (FY21: 96m users, 187m page views). The company believes that FY21 numbers were boosted by heightened interest in health information during the pandemic.
■
The number of companies partnered with EMIS increased to 175 from 148 a year ago.
■
Two new EMIS-X Analytics products were launched in the year: Recruit, which provides a technological link to support efficient recruitment into clinical trials, and Pathway, which uses clinical intelligence to identify cohorts of patients at risk of long-term health conditions. Pathway is currently being used to facilitate the NHS England hepatitis C virus elimination programme.
Exhibit 3: Financial summary
£'000s |
2018 |
2019 |
2020 |
2021 |
2022 |
||
Year end 31 December |
|||||||
PROFIT & LOSS |
|||||||
Revenue |
|
|
149,710 |
159,507 |
159,453 |
168,226 |
175,373 |
Cost of Sales |
(14,236) |
(15,407) |
(20,335) |
(16,255) |
(12,901) |
||
Gross Profit |
135,474 |
144,100 |
139,118 |
151,971 |
162,472 |
||
EBITDA |
|
|
48,919 |
55,632 |
53,536 |
54,707 |
59,381 |
Operating Profit (before amort. of acq. intang, SBP and except.) |
32,991 |
40,794 |
43,020 |
43,246 |
47,631 |
||
EMIS adjusted operating profit |
|
|
35,890 |
39,273 |
39,266 |
43,533 |
47,686 |
Amortisation of acquired intangibles |
(6,202) |
(7,317) |
(6,824) |
(5,673) |
(5,190) |
||
Exceptionals |
1,657 |
(5,360) |
1,802 |
0 |
(12,762) |
||
Share-based payments |
(766) |
(1,290) |
(1,440) |
(1,788) |
(1,933) |
||
Operating Profit |
27,680 |
26,827 |
36,558 |
35,785 |
27,746 |
||
Net Interest |
(180) |
(498) |
(501) |
(426) |
(51) |
||
Profit Before Tax (norm) |
|
|
33,426 |
41,038 |
43,377 |
43,547 |
48,113 |
Profit Before Tax (FRS 3) |
|
|
28,115 |
27,071 |
36,915 |
36,086 |
38,934 |
Tax |
(5,355) |
(5,022) |
(6,794) |
(7,010) |
(5,764) |
||
Profit After Tax (norm) |
26,447 |
33,697 |
35,658 |
35,065 |
38,972 |
||
Profit After Tax (FRS3) |
22,760 |
22,049 |
30,121 |
29,076 |
33,170 |
||
Average Number of Shares Outstanding (m) |
63.0 |
62.9 |
62.9 |
63.0 |
63.1 |
||
EPS - normalised & diluted (p) |
|
|
40.4 |
53.5 |
56.4 |
55.0 |
60.9 |
EPS - EMIS adjusted & diluted (p) |
|
|
45.0 |
51.1 |
50.4 |
55.5 |
61.2 |
EPS - FRS 3 (p) |
|
|
36.1 |
36.0 |
48.1 |
46.2 |
52.5 |
Dividend (p) |
28.4 |
31.2 |
32.0 |
35.2 |
38.7 |
||
Gross Margin (%) |
90.5% |
90.3% |
87.2% |
90.3% |
92.6% |
||
EBITDA Margin (%) |
32.7% |
34.9% |
33.6% |
32.5% |
33.9% |
||
Operating Margin (before GW and except.) (%) |
22.0% |
25.6% |
27.0% |
25.7% |
27.2% |
||
BALANCE SHEET |
|||||||
Fixed Assets |
|
|
117,920 |
101,089 |
105,518 |
95,584 |
139,190 |
Intangible Assets |
96,807 |
82,345 |
85,295 |
76,535 |
124,188 |
||
Tangible Assets |
21,000 |
18,399 |
19,870 |
18,694 |
14,803 |
||
Other fixed assets |
113 |
345 |
353 |
355 |
199 |
||
Current Assets |
|
|
53,107 |
67,278 |
87,170 |
101,359 |
85,579 |
Stocks |
1,264 |
657 |
613 |
530 |
518 |
||
Debtors |
36,223 |
33,047 |
29,993 |
32,057 |
38,889 |
||
Cash |
15,620 |
31,099 |
53,008 |
64,042 |
45,918 |
||
Current Liabilities |
|
|
(60,169) |
(55,700) |
(63,370) |
(61,665) |
(70,722) |
Creditors |
(60,169) |
(55,060) |
(62,380) |
(60,762) |
(70,017) |
||
Lease liabilities |
0 |
(640) |
(990) |
(903) |
(705) |
||
Short term borrowings |
0 |
0 |
0 |
0 |
0 |
||
Long Term Liabilities |
|
|
(8,199) |
(8,469) |
(10,180) |
(6,801) |
(11,576) |
Long term borrowings |
0 |
0 |
0 |
0 |
0 |
||
Lease liabilities |
0 |
(3,294) |
(5,891) |
(5,013) |
(3,660) |
||
Other long term liabilities |
(8,199) |
(5,175) |
(4,289) |
(1,788) |
(7,916) |
||
Net Assets |
|
|
102,659 |
104,198 |
119,138 |
128,477 |
142,471 |
CASH FLOW |
|||||||
Operating Cash Flow |
|
|
49,873 |
50,059 |
64,138 |
50,059 |
48,813 |
Net Interest |
(214) |
(93) |
(54) |
(64) |
55 |
||
Tax |
(5,830) |
(4,466) |
(11,684) |
(7,483) |
(2,659) |
||
Capex |
(12,767) |
(13,119) |
(9,491) |
(6,405) |
(7,106) |
||
Acquisitions/disposals |
(9,269) |
5,152 |
(953) |
(1,990) |
(34,589) |
||
Financing |
906 |
(2,369) |
1,324 |
(780) |
736 |
||
Dividends |
(21,070) |
(18,745) |
(19,860) |
(21,146) |
(22,193) |
||
Net Cash Flow |
1,629 |
16,419 |
23,420 |
12,191 |
(16,943) |
||
Opening net debt/(cash) |
|
|
(13,991) |
(15,620) |
(31,099) |
(53,008) |
(64,042) |
Finance leases initiated |
0 |
(940) |
(1,511) |
(1,157) |
(1,181) |
||
Other |
0 |
0 |
0 |
0 |
0 |
||
Closing net debt/(cash) |
|
|
(15,620) |
(31,099) |
(53,008) |
(64,042) |
(45,918) |
Source: EMIS Group accounts
|
|
Research: Industrials
Increasing European legislation for recycling and recycled content provides a positive backdrop for Renewi as a waste treatment company (63.6% of waste treated was recycled in FY23). Stable FY23 results in a more challenging economic environment offer a solid platform for the management to deliver on its new target to grow sales (and profit given the margin expectations) by c 50% over the next five years.